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ORIGINAL ARTICLE
Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists
in men with advanced, non-metastatic prostate cancer: a register-based,
observational study
Frederik Birkebæk Thomsena, Cecilia Boscob, Hans Garmob,c , Jan Adolfssond, Niklas Hammare,f,
P€ar Statting and Mieke Van Hemelrijckb,e
aCopenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
bTranslational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK;
cRegional Cancer Centre Uppsala €Orebro, Uppsala University Hospital, Uppsala, Sweden; dCLINTEC-department, Karolinska Institutet,
Stockholm, Sweden; eUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; fMedical
Evidence and Observational Research, Global Medicines Development, AstraZeneca, Stockholm, Sweden; gDepartment of Surgical Sciences,
Uppsala University Hospital, Uppsala, Sweden
ABSTRACT
Background: In randomised controlled trials, men with advanced, non-metastatic prostate cancer
(PCa) treated with anti-androgen monotherapy (AA) had similar all-cause mortality as men treated
with gonadotropin-releasing hormone (GnRH) agonists. Using real-world evidence (i.e., observational
data), we aimed to further assess the difference in mortality between these two drug categories.
Material and Methods: We emulated a trial using data from Prostate Cancer data Base Sweden 3.0.
We specifically focused on men diagnosed in 2006–2012 with high-risk PCa who had no distant metas-
tasis. They either received primary hormonal therapy with AA (n¼ 2078) or GnRH agonists (n¼ 4878)
who were followed for a median time of 5 years. Risk of death from PCa and other causes was
assessed using competing risk analyses and Cox proportional hazards regression analyses, including
propensity score matching.
Results: The cumulative 5-year PCa mortality was lower for men treated with AA (16% [95% confi-
dence interval, CI, 15–18%]) than men treated with GnRH agonists (22% [95% CI 21–24%]). The 5-year
other cause mortality was also lower for men on AA (17% [95% CI 15–19%] compared to men on
GnRH agonists (27% [95% CI 25–28%]). In regression analyses, the risk of PCa death was similar, GnRH
agonists versus AA (reference), hazard ratio (HR) 1.08 (95% CI 0.95–1.23), but the risk of death from all
causes was higher for men on GnRH agonists, HR 1.23 (95% CI 1.13–1.34). Consistent results were
seen in the propensity score-matched cohort.
Conclusion: Our results indicate that the use of AA as primary hormonal therapy in men with high-
risk non-metastatic PCa does not increase PCa-specific mortality compared to GnRH. Using AA instead
of GnRH agonists may result in shorter time on/exposure to GnRH-treatment, which may reduce the
risk of adverse events associated with this treatment.
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Introduction
Radiotherapy with adjuvant hormonal therapy is the recom-
mended treatment for men with high-risk prostate cancer
(PCa) with no distant metastasis [1]. However, a substantial
number of these men start primary hormonal therapy with-
out radiotherapy, especially men with prostate specific-
antigen (PSA) levels above 50 ng/mL and/or locally advanced
PCa (clinical local stage T3-4) [2,3]. Moreover, around 20% of
men diagnosed with localised PCa who received primary
curative treatment will require hormonal therapy within 10
years [4].
The two main types of hormonal therapy for high-risk PCa
with no distant metastasis are anti-androgen monotherapy
(AA) and gonadotropin-releasing hormone (GnRH) agonists
[5]. Their mechanism of action is very different. AAs competi-
tively bind to androgen receptors, resulting in a decline in
testosterone biosynthesis [6,7]. In contrast, GnRH agonists
bind GnRH receptors on pituitary gonadotropin-producing
cells, which causes a temporary release of LH and FSH. Thus,
AA have less effect on a reduction of testosterone levels in
the circulation as compared to GnRH agonists [8].
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The adverse events profile for these two treatments is dif-
ferent, mainly due to these different effects on circulating
testosterone levels. For men on AA, the most frequent
adverse events are breast pain and gynaecomastia (due to
conversion of testosterone into estradiol), while liver toxicity
is a rare but serious event [9,10]. For men on GnRH ago-
nists, the most common adverse events are hot flushes,
weight gain, loss of libido and erectile dysfunction [8].
Additionally, GnRH agonists are associated with a number
of long-term adverse metabolic effects including bone loss
and increased risk of fractures [11], cardiovascular disease
[12,13], diabetes mellitus type 2 [12] and possibly dementia
[14]. Low levels of androgens have been shown to increase
levels of low-density lipoprotein (LDL), triglycerides and
insulin – all risk factors of ardiovascular disease [15].
Furthermore, testosterone may be protective against the
development of atheromatous plaques by causing coronary
artery dilation and inhibiting the effect of pro-inflammatory
cytokines [16].
The current EAU-ESTRO-SIOG guidelines do not recom-
mend AA with bicalutamide 150 mg/daily as standard of
care for men with high-risk PCa with no distant metastasis
[1]. This recommendation is based on a Cochrane review,
which concluded that AA in men with advanced PCa is less
effective than castration in terms of overall survival [17].
However, this review included studies with different types of
AA and different dosages. Furthermore, in the subgroup ana-
lysis of men with advanced, non-metastatic PCa treated with
bicalutamide 150 mg/daily, overall survival was similar to cas-
tration, in line with two randomised controlled trials (RCTs)
[18,19]. These two RCTs specifically compared the clinical
effectiveness as well as adverse events of bicalutamide 150
mg/daily versus GnRH agonists or maximal androgen block-
ade (GnRH agonist combined with continuous AA). Although
the statistical requirement for non-inferiority was not met,
survival was similar between the group of men treated GnRH
agonists and those treated with bicalutamide 150 mg/daily.
Based on these trials, the European Medicines Agency subse-
quently approved this AA for use in men with advanced,
non-metastatic PCa [20].
Even though RCTs are considered the gold standard for
evaluating the effectiveness of interventions, observational
data, also known as real-world data, is an important addition
to RCTs in clinical decision making provided that confound-
ing by indication is appropriately handled [21]. Compared to
patients outside RCTs, participants in RCTs are often highly
selected with smaller cancer burden, and elderly patients
and those with comorbidities are frequently excluded [22,23].
Thus, additional evidence from observational studies in sup-
port of results from RCTs is needed to show the external val-
idity of these results.
When PCa cells escape the control of AA leading to dis-
ease progression, men on AA will switch to GnRH agonists
[24]. Consequently, men who start on AA are less exposed to
the broad/severe systemic and metabolic side effects of
GnRH agonists than those who start on GnRH agonists.
Hence, evaluating possible differences in PCa specific
mortality and overall mortality amongst those starting on AA
versus those starting on GnRH agonists is important.
We aimed to further investigate the potential difference
in mortality between primary AA and GnRH agonists, by sup-
plementing existing RCT evidence using real-world data.
Patients and methods
Data resource
The current study is based on data from Prostate Cancer
data Base Sweden (PCBaSe) 3.0, which contains information
on cancer characteristics and primary treatment from the
National Prostate Cancer Register (NPCR) of Sweden [24].
Data on comorbidity were obtained from the Patient
Registry, data on educational level, income and marital status
from the LISA database, and cause and date of death from
the National Cause of Death Registry.
Target trial
To ensure clinically meaningful results by use of real-world
data, we used the ROBINS-I tool to emulate a target trial for
risk of death in men on GnRH agonists or AA [25]. A target
trial is a pragmatic trial that resembles a hypothetical RCT
using observational data. Such an approach is considered
useful when designing an observational study to assess the
effects of different types of drugs. The ROBINS-I tool was
used to assess potential biases before, during and after inter-
vention in this study (See Supplemental Appendix) [25]. This
tool was specifically designed to evaluate the risk of bias in
comparative effectiveness studies that do not use randomisa-
tion to allocate individuals to comparison groups.
For this study, we selected all men from PCBaSe aged
90 years who were diagnosed with high-risk or regionally
metastatic PCa, i.e., clinical local stage T3 or higher and/or
PSA 20 ng/mL or higher and/or Gleason Grade Group 4–5
and/or N1 and no distant metastases. We specifically selected
men diagnosed in 2006–2012 who received AA or GnRH ago-
nists as primary therapy. The study then set out to compare
AA monotherapy (150 mg/daily) with GnRH agonists. The
large majority of men on AA received bicalutimide, for which
adherence has previously been shown to be very good [26].
This information, as well as conversion from AA to GnRH
agonists, was verified through data on filled prescriptions in
the Prescribed Drug Registry. In case of disease progression,
the switch to GnRH agonists was allowed and handled based
on the intention-to-treat approach.
Follow-up was then calculated from the date of PCa diag-
nosis until death, emigration or date of censoring, whichever
event came first. End of follow-up was 31 December 2015 for
those analyses focused on PCa mortality, and 31 December
2016 for those analyses focused on all-cause mortality.
The Research Ethics Board at Umeå University Hospital
approved the study.
2 F. B. THOMSEN ET AL.
Imputation
To handle missing data for potential confounding factors, we
performed multiple imputation using the method of Chained
Equations and the MICE package [27]. Data were missing for
the following variables: mode of detection (3% missing), T
stage (1% missing), N stage (0.3% missing), Gleason Grade
Groups (5% completely missing and 1% not differentiating
between GGG1 or GGG2), percent positive biopsies (25%
missing), PSA (1% missing) and education (1% missing).
Moreover, to account for differential misclassification of
M1 disease, which included Mx when no bone scan was
performed (prior to 2011), we conducted an inputation of M
status (50% were recorded as Mx). In our imputation models,
we included information from all men with intermediate-,
high-risk, regionally metastatic and metastatic disease who
were treated with primary hormonal therapy (Supplemental
Table 1). The number of multiple imputations was set to five.
All subsequent analyses were conducted using the imputed
data sets, for men originally categorised with high-risk or
regionally metastatic PCa, but excluding those with imputed
M1 disease. A sensitivity analysis ignoring imputed M1 disease
was also performed.
Statistical methods
First, we created cumulative incidence graphs showing PCa-
specific death, overall death, and conversion from AA to GnRH
agonists. Then, we conducted both traditional Cox propor-
tional hazards regression analyses as well as propensity score-
matched analyses within the target trial population. The latter
allowed for a detailed assessment of our real-world data.
Cox proportional hazards regression analyses
We conducted uni- and multivariate Cox proportional hazards
regression analyses for death of PCa and death from all causes
using age as a timescale, whilst adjusting for year of diagnosis
(continuous), mode of detection (categorical), T stage (categor-
ical), Gleason Grade Groups (categorical), proportion positive
biopsy cores (modelled as an interaction with T stage in men
not diagnosed following TUR-P with two spine knots), PSA at
diagnosis (categorical), bone imaging performed (dichotom-
ised), Charlson comorbidity index (categorical), marital status
(categorical) and education level (categorical). Results are pre-
sented as Hazard ratios (HR) with 95% confidence intervals (CI).
Propensity score matched analyses
We then conducted additional Cox model analysis based on
propensity score matching for the type of hormonal therapy.
Propensity score matching was done with the MatchIt pack-
age for R using a caliper of 0.1 and included the covariates
enumerated above. Subsequent multivariable Cox proportional
hazards regression analyses were performed adjusting for the
Figure 1. CONSORT diagram.
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covariates used to perform the propensity score matching.
Finally, we created 1-Kaplan-Meier estimates of PCa-specific
and overall survival for the propensity score matched groups.
All statistical analysis was performed with R version 3.1.2
(R Foundation for Statistical Computing, Vienna, Austria).
Table 1. Baseline characteristics of men in PCBaSe 3.0 diagnosed with high-risk and regionally metastatic prostate cancer in 2006–2012 and treated with anti-
androgen monotherapy or GnRH agonists.
Raw Imputed Propensity score matched
Anti-
androgens
(n¼ 2078)
GnRH
agonists
(n¼ 4878)
Anti-
androgens
(n¼ 2060)
GnRH
agonists
(n¼ 4740)
Anti-
androgens
(n¼ 1975)
GnRH
agonists
(n¼ 1975)
n % n % n % n % n % n %
Year of diagnosis
2006–2007 542 26.1 1692 34.7 538 26.1 1638 34.6 527 26.7 547 27.7
2008–2010 559 26.9 1476 30.3 548 26.6 1415 29.9 532 26.9 532 26.9
2011–2012 977 47.0 1710 35.1 974 47.3 1687 35.6 916 46.4 896 45.4
Age at diagnosis, years
<70 328 15.8 699 14.3 327 15.9 681 14.4 311 15.7 357 18.1
70–74 414 19.9 751 15.4 409 19.9 735 15.5 382 19.3 342 17.3
75–79 688 33.1 1287 26.4 682 33.1 1247 26.3 654 33.1 548 27.7
80–84 470 22.6 1367 28.0 464 22.5 1323 27.9 454 23.0 485 24.6
85–90 178 8.6 774 15.9 178 8.6 754 15.9 174 8.8 243 12.3
Mode of detection
Screening 562 27.1 933 19.1 575 27.9 936 19.7 536 27.1 510 25.8
LUTS 1016 48.9 2836 58.2 1045 50.7 2852 60.2 1021 51.7 1058 53.6
Symptoms 431 20.8 966 19.8 440 21.4 952 20.1 418 21.2 407 20.6
Missing 67 3.2 139 2.9
Clinical tumour category
T1a 3 0.1 13 0.3 3 0.1 13 0.3 3 0.2 2 0.1
T1b 29 1.4 66 1.4 30 1.5 66 1.4 30 1.5 28 1.4
T1c 374 18.0 640 13.1 375 18.2 639 13.5 342 17.3 335 17.0
T2 639 30.8 1634 33.5 645 31.3 1612 34.0 629 31.8 652 33.0
T3 937 45.1 2207 45.2 932 45.2 2157 45.5 897 45.4 882 44.7
T4 76 3.7 262 5.4 75 3.6 253 5.3 74 3.7 76 3.8
TX 20 1.0 56 1.1
N stage
N0 150 7.2 262 5.4 150 7.3 263 5.5 145 7.3 133 6.7
N1 66 3.2 211 4.3 66 3.2 207 4.4 66 3.3 64 3.2
NX 1857 89.4 4392 90.0 1844 89.5 4270 90.1 1764 89.3 1778 90.0
Missing 5 0.2 13 0.3
Gleason Grade Group
GGG1 269 12.9 382 7.8 274 13.3 394 8.3 254 12.9 221 11.2
GGG2 412 19.8 652 13.4 444 21.6 725 15.3 415 21.0 385 19.5
GGG3 409 19.7 846 17.3 433 21.0 908 19.2 410 20.8 410 20.8
GGG4 547 26.3 1273 26.1 564 27.4 1308 27.6 552 27.9 568 28.8
GGG5 328 15.8 1377 28.2 345 16.7 1405 29.6 344 17.4 391 19.8
Missing 113 5.4 348 7.1
Percent positive biopsy cores
0–49% 452 21.8 623 12.8 570 27.7 838 17.7 528 26.7 507 25.7
50–74% 459 22.1 777 15.9 562 27.3 1049 22.1 526 26.6 499 25.3
75–100% 733 35.3 2121 43.5 928 45.0 2853 60.2 921 46.6 969 49.1
Missing 434 20.9 1357 27.8
PSA at diagnosis, ng/ml
<3 22 1.1 44 0.9 23 1.1 43 0.9 23 1.2 18 0.9
3–10 238 11.5 483 9.9 238 11.6 477 10.1 223 11.3 230 11.6
10–20 387 18.6 846 17.3 388 18.8 840 17.7 376 19.0 376 19.0
20–50 993 47.8 2151 44.1 988 48.0 2111 44.5 936 47.4 936 47.4
50þ 423 20.4 1277 26.2 423 20.5 1269 26.8 417 21.1 415 21.0
Missing 15 0.7 77 1.6
Charlson comorbidity index
0 1217 58.6 2702 55.4 1206 58.5 2618 55.2 1148 58.1 1168 59.1
1 506 24.4 1153 23.6 501 24.3 1124 23.7 486 24.6 459 23.2
2 208 10.0 577 11.8 206 10.0 565 11.9 199 10.1 205 10.4
3þ 147 7.1 446 9.1 147 7.1 433 9.1 142 7.2 143 7.2
Marital status
Married 1388 66.8 3057 62.7 1375 66.7 2969 62.6 1315 66.6 1335 67.6
Not married 690 33.2 1821 37.3 685 33.3 1771 37.4 660 33.4 640 32.4
Education level
High 392 18.9 679 13.9 394 19.1 670 14.1 367 18.6 335 17.0
Middle 716 34.5 1590 32.6 717 34.8 1564 33.0 682 34.5 689 34.9
Low 948 45.6 2532 51.9 949 46.1 2506 52.9 926 46.9 951 48.2
Missing 22 1.1 77 1.6
Results obtained after imputation of missing values and following matching on propensity score. Results from the first imputed dataset presented.
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Results
The study population consisted of 2078 men on AA and 4878
men on GnRH agonists as primary hormonal therapy (Figure 1).
The median follow-up was 4.7 years, representing a total of
28,315 person-years. Men treated with AA were younger,
diagnosed in more recent calendar years, had less adverse
cancer characteristics and had higher education level, com-
pared to men treated with GnRH agonists (Table 1). Across
the 5 imputed datasets, the number with imputed M1 dis-
ease ranged from 7 to 20 (mean =14) amongst those treated
with AA and from 109 to 162 (mean =140) amongst those
treated with GnRH agonists. In total, 765 (37%) men con-
verted from AA to GnRH agonists, with a median time of
exposure to AA of 4.3 years (95% CI 4.1–4.6) (Figure 2).
The 5-year crude cumulative incidence of PCa mortality
for men on AA was lower than men on GnRH agonists (AA
16% [95% CI 15–18%] vs. GnRH agonists 22% [95% CI
21–24%]). The 5-year cumulative mortality incidence of other
causes than PCa was also lower for men on AA than men on
GnRH agonists (AA 17% [95% CI 15–19%] and GnRH agonists
27% [95% CI 25–28%]) (Figure 3).
Using the traditional Cox proportional hazards regression
analyses, we found that men who received GnRH agonists
had a similar risk of death from PCa as men on AA, HR 1.08
(95% CI 0.95–1.23), but a higher risk of death from all causes,
HR 1.23 (95% CI 1.13–1.34) (Table 2). Stratification by PCa
risk category revealed similar results, with the exception of
no difference in death from all causes in men with regional
metastatic PCa, HR 1.09 (95% CI 0.94–1.26).
Following propensity score matching, a total of
1972–1976 men were identified in each treatment group in
the 5 imputed datasets. Similar to the results of the trad-
itional multivariable Cox analyses, men on GnRH agonists
had a similar risk of death from PCa as men on AA, HR 1.09
(95% CI 0.94–1.27), but a higher risk of death from all causes,
HR 1.25 (95% CI 1.14–1.37) (Table 3). Stratification by PCa
risk category revealed similar results, again with the excep-
tion of men with regionally metastatic PCa for whom there
was no difference in deaths from all causes. Figure 4 shows
the 1-Kaplan-Meier curves for PCa-specific death and all
deaths. While there was no statistically significant difference
in 5-year PCa-specific mortality, the 5-year all-cause mortality
was lower for men on AA (32% [95% CI 30–35%]) than for
men on GnRH agonists (42% [95% CI 39–45%)].
In a sensitivity analysis, we evaluated the effect of inclu-
sion of imputed M1 disease in our regression models. This
showed that our exclusion of M1disease attenuated the dif-
ference in risk of death between AA and GnRH agonsits,
which highlights the importance of having correct staging
information.
Discussion
In this register-based, observational study of men with high-
risk PCa with no distant metastasis, treated with primary hor-
monal therapy, men on AA had similar PCa mortality and
lower all-cause mortality than men on GnRH agonists.
There are two ways to interpret our results. Firstly, these
findings could represent the true effect of two treatments
which are known to have different mechanisms of action
and different side-effect profiles. Alternatively, our results
could be due to the effect of bias, given the observational
nature of this study design. Even though RCTs are consid-
ered the gold standard for comparisons of treatments, it has
now been recognised that clinical trials may fail to show clin-
ical effectiveness [23]. The guidelines from the European
GetReal consortium (‘incorporating real-life data into drug
development’) specifically recommend considering evidence
from pragmatic trials and non-randomised studies to
improve applicability of treatment effect estimates, inform
disconnected or scarce networks of evidence, identify patient
populations that will likely receive the drug after launch, and
to improve relevant to decision/policy makers and patients
[22]. In the current register-based, observational study, all
men with relevant cancer characteristics were included
regardless of other characteristics, with the exception of very
high age (older than 90 years of age) and a previous can-
cer diagnosis.
A general limitation of observational studies is the lack of
randomisation and possible impact of bias caused by treat-
ment selection. Hence, to evaluate the potential risk of bias,
we used the ROBINS-I tool (Supplemental Appendix 1). After
carefully assessing each of the domains outlined in the
ROBINS-I tool, we concluded that the overall risk of bias was
moderate. Therefore, our study provides sound evidence for
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Figure 2. First event of conversion from AA to GnRH agonist, death from other
causes or death from PCa assessed in competing risk analyses among men who
started on anti-androgen monotherapy (AA) in competing risk analyses.
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a non-randomised study, but cannot be considered compar-
able to a well-performed RCT. Consequently, our results are
deemed to be hypothesis-generating.
In the current study, men managed with AA were
younger, diagnosed in more recent calendar years, had less
comorbidities and had less adverse cancer characteristics
compared to men treated with GnRH agonists. We adjusted
for these differences in the traditional Cox regression analy-
ses and found similar risk of PCa death in men on AA and
men on GnRH agonists. However, we also observed a lower
all-cause mortality among men with high-risk PCa treated
with AA, while men with regional metastatic PCa had similar
risk of deaths from all causes, in line with results from previ-
ous RCTs [18,19]. Unmeasured confounders are likely to
account for some of this difference.
To further adjust for differences between treatment
groups, we identified propensity score-matched groups of
men on AA and men on GnRH agonists. A well-matched pro-
pensity score analysis is based on balanced baseline patient
characteristics and excludes exposed participants who had
no comparable unexposed participant and vice versa [28].
Propensity score matching does not assume linearity in the
relationship between the propensity and outcome and
allows for simple, transparent analyses. It provides a better
balance of covariates between exposed and unexposed
groups compared to other matching strategies in datasets
with many covariates [29]. The propensity score-matched
analyses revealed similar results as the traditional multivari-
able Cox regression analyses – which is not surprising given
the number of detailed covariates available in this large data-
set [30].
As previously mentioned, men who started on AA
switched to GnRH agonists after about 4.3 years. Our results
showing no difference in PCa-specific mortality and lower
overall mortality in the AA group, suggest that AA can be
considered as an initial alternative therapy for men with
locally advanced PCa. Nevertheless, it is important to note
that our study design used intention to treat rather than per
protocol analysis. The former ensures comparability between
groups that are obtained through randomisation (propensity
score matching in this particular setting) and maintains sam-
ple size. Hence, one of the limitations of our study is poten-
tial dilution of the treatment effect estimation due to
noncompliance [31].
The main limitation of our study was the non-random
allocation to type of hormonal therapy, with ensuing
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Figure 3. Cumulative probability of death from PCa or death from other causes for men on anti-androgen monotherapy (AA) and men on GnRH agonists.
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Table 2. Risk of death from prostate cancer or death from all causes in men on primary anti-androgen monotherapy or GnRH agonists.
All men with high-risk and
regionally metastatic
prostate cancer Men with high-risk prostate cancer
Men with regionally metastatic
prostate cancer
Death from
prostate cancer
Death from
all causes
Death from
prostate cancer
Death from
all causes
Death from
prostate cancer
Death from
all causes
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Anti-androgen monotherapy 1.00 ref 1.00 ref 1.00 ref 1.00 ref 1.00 ref 1.00 ref
GnRH agonists
Crude model using age as time scale 1.39 1.23–1.57 1.45 1.34–1.57 1.45 1.24–1.69 1.50 1.37–1.65 1.16 0.96–1.42 1.26 1.09–1.46
Adjustment
T stage 1.37 1.21–1.55 1.45 1.34–1.57 1.44 1.23–1.68 1.51 1.37–1.66 1.16 0.95–1.41 1.26 1.09–1.46
Gleason Grade Group 1.21 1.07–1.37 1.37 1.27–1.48 1.25 1.07–1.47 1.44 1.30–1.58 1.06 0.87–1.29 1.19 1.03–1.37
PSA 1.19 1.05–1.34 1.36 1.25–1.47 1.24 1.06–1.46 1.43 1.30–1.57 1.04 0.85–1.27 1.18 1.02–1.36
Proportion positive biopsy cores 1.15 1.01–1.30 1.34 1.23–1.45 1.19 1.01–1.39 1.40 1.27–1.55 1.02 0.84–1.25 1.17 1.01–1.35
Imaging performed 1.11 0.98–1.25 1.29 1.19–1.40 1.15 0.98–1.34 1.36 1.23–1.50 0.96 0.79–1.18 1.11 0.96–1.29
Time between diagnosis and start of treatment 1.11 0.98–1.26 1.29 1.19–1.40 1.15 0.98–1.35 1.36 1.23–1.50 0.97 0.79–1.18 1.11 0.95–1.28
Mode of detection 1.10 0.97–1.25 1.28 1.18–1.39 1.13 0.96–1.33 1.34 1.21–1.48 0.96 0.78–1.18 1.10 0.95–1.28
Year of diagnosis 1.09 0.96–1.23 1.27 1.17–1.38 1.12 0.95–1.31 1.33 1.20–1.47 0.96 0.78–1.17 1.10 0.95–1.28
CCI 1.08 0.96–1.23 1.25 1.15–1.36 1.11 0.95–1.31 1.30 1.18–1.43 0.96 0.78–1.17 1.10 0.95–1.27
Marital status 1.08 0.96–1.23 1.24 1.14–1.35 1.11 0.95–1.31 1.29 1.17–1.43 0.96 0.78–1.17 1.09 0.94–1.26
Education 1.08 0.95–1.23 1.23 1.13–1.34 1.11 0.94–1.31 1.28 1.16–1.41 0.96 0.78–1.17 1.09 0.94–1.26
Hazard ratios calculated by use of Cox regression analyses.High-risk prostate cancer: T3 and/or PSA 20 ng/ml or higher and lower than 50 ng/ml and/or Gleason Grade Group 4–5.Regionally metastatic prostate cancer: T4 and/or PSA 50 ng/ml or higher and lower than 100 ng/ml or N1.Modelled using a linear spline with knots in PSA 3, 10, 20 and 50.Modelled as an interaction with T stage in men not diagnosed following TUR-P.
Table 3. Risk of death from prostate cancer or death from all causes for men on primary GnRH agonists or anti-androgen monotherapy (AA,
reference in analyses) following propensity score matching.
Including all men with a match
Number of men in group
No of events Crude Adjusted
AA GnRH HR 95% CI HR 95% CI
High-risk and regionally metastatic prostate cancer
Death from prostate cancer 1975 348 371 1.09 0.94–1.26 1.05 0.90–1.23
Death from all causes 1975 702 858 1.25 1.13–1.38 1.23 1.11–1.36
High-risk prostate cancer
Death from prostate cancer 1436 209 239 1.15 0.91–1.45 1.12 0.88–1.42
Death from all causes 1436 473 619 1.33 1.18–1.50 1.29 1.14–1.46
Regionally metastatic prostate cancer
Death from prostate cancer 506 132 123 0.96 0.72–1.28 0.93 0.69–1.43
Death from all causes 506 215 237 1.11 0.89–1.37 1.12 0.89–1.40
Hazard ratios calculate by use of Cox regression analyses. The median time from diagnosis to start of treatment was 16 days longer for men
on AA compared to men on GnRH agonists.Number of men in the first of the imputed dataset.High-risk prostate cancer: T3 and/or PSA 20 ng/ml or higher and lower than 50 ng/ml and/or Gleason Grade Group 4–5.Regionally metastatic prostate cancer: T4 and/or PSA 50 ng/ml or higher and lower than 100 ng/ml or N1.
Figure 4. Probability of PCa death and death from all causes following propensity score matched for men on anti-androgen monotherapy (AA) and GnRH agonists,
assessed with 1-Kaplan-Meier estimates.
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channelling bias of younger and healthier men with less
advanced cancer to receive AA. However, we used a robust
study design with application of propensity score matching
with fairly well-balanced baseline characteristics in the two
treatment arms. Yet this method is based on measured varia-
bles, thus residual confounding is likely to be present as in
most observational studies. Strengths of our study include
the nationwide, population-based cohort of men with
comprehensive data from a clinical cancer register with
documented high data quality as well as several other
high-quality health care registers [32,33], a setting that thus
provides strong real-world data.
Conclusion
Using a hypothetical trial in a real-world setting, our results
indicate that in men with high-risk PCa with no distant
metastasis, PCa-specific mortality is similar for those treated
with AA and those treated with GnRH agonists. However, all-
cause mortality was lower for men taking AA compared with
men on GnRH agonists. Starting on AA instead of GnRH ago-
nists may result in less exposure to GnRH agonists and hence
potentially less risk of adverse events.
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